Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Oxyntomodulin inhibits food intake in the rat
Autore:
Dakin, CL; Gunn, I; Small, CJ; Edwards, CMB; Hay, DL; Smith, DM; Ghatei, MA; Bloom, SR;
Indirizzi:
Hammersmith Hosp, Dept Metab Med, Imperial Coll, Sch Med,Endocrine Unit, London W12 0NN, England Hammersmith Hosp London England W12 0NN ne Unit, London W12 0NN, England
Titolo Testata:
ENDOCRINOLOGY
fascicolo: 10, volume: 142, anno: 2001,
pagine: 4244 - 4250
SICI:
0013-7227(200110)142:10<4244:OIFIIT>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUCAGON-LIKE PEPTIDE-1; GASTRIC-ACID SECRETION; BIOACTIVE ENTEROGLUCAGON; RECEPTOR AGONISTS; GLP-1 RECEPTOR; BINDING-SITES; EXENDIN-4; GLUCOSE; ANTAGONIST; CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Bloom, SR Hammersmith Hosp, Dept Metab Med, Imperial Coll, Sch Med,Endocrine Unit, London W12 0NN, England Hammersmith Hosp London England W12 0NN ondon W12 0NN, England
Citazione:
C.L. Dakin et al., "Oxyntomodulin inhibits food intake in the rat", ENDOCRINOL, 142(10), 2001, pp. 4244-4250

Abstract

Oxyntomodulin is derived from proglucagon processing in the intestine and the central nervous system. To date, no role in the central nervous system has been demonstrated. We report here that oxyntomodulin inhibits refeedingwhen injected intracerebroventricularly and into the hypothalamic paraventricular nucleus of 24-h fasted rats [intracerebroventricularly and into theparaventricular nucleus, 1 h, oxyntomodulin (1 nmol), 3.1 +/- 0.5 g; saline, 6.2 +/- 0.4 g; P < 0.005]. In addition, oxyntomodulin inhibits food intake in nonfasted rats injected at the onset of the dark phase (intracerebroventricularly, I h: oxyntomodulin, 3 nmol, 1.1 +/- 0.19 g vs. saline, 2.3 +/- 0.2 g; P < 0.05). This effect of oxyntomodulin on feeding is of a similartime course and magnitude as that of an equimolar dose of glucagon-like peptide-1. Other proglucagon-derived products investigated [glucagon, glicentin (intracere-broventricularly, 3 nmol; into the paraventricular nucleus, 1nmol), and spacer peptide-1 (intracerebroventricularly and into the paraventricular nucleus, 3 nmol)] had no effect on feeding at any time point examined. The anorectic effect of oxyntomodulin (intracerebroventricularly, 3 nmol; into the paraventricular nucleus, 1 nmol) was blocked when it was coadministered with the glucagon-like peptide-1 receptor antagonist, exendin-(9-39) (intracerebroventricularly, 100 nmol; into the paraventricular nucleus, 10 nmol). However, oxyntomodulin has a lower affinity for the glucagon-like peptide-1 receptor compared with glucagon-like peptide-1 (IC50: oxyntomodulin, 8.2 nM, glucagon-like peptide-1, 0.16 nM). One explanation for this is that there might be an oxyntomodulin receptor to which exendin-(9-39) can also bind and act as an antagonist.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 15:43:38